|
시장보고서
상품코드
2086832
체액 분석 시장 : 제품별, 기술별, 유형별, 체액 유형별, 용도별, 최종사용자별, 지역별 - 세계 예측(-2031년)Body Fluid Analysis Market by Product (Consumables, Instruments), Technology (Immunoassay, PCR, Flow Cytometry), Fluid Type (CSF, Pleural, Synovial, Peritoneal, Semen), Application (Clinical Diagnostics, Forensic, Research) - Global Forecast to 2031 |
||||||
체액 분석 시장 규모는 2026년 26억 2,000만 달러에서 2031년까지 36억 5,000만 달러로 성장할 것으로 예상되며, CAGR은 6.9%에 달할 것으로 예측됩니다.
알츠하이머병이나 파킨슨병과 같은 신경계 질환의 유병률 증가가 뇌척수액(CSF) 바이오마커 검사 수요를 견인하고 있는 반면, 근골격계 질환 및 인공관절 주위 감염증의 발생률 증가로 인해 활액 분석의 활용이 확대되고 있습니다.
| 조사 범위 | |
|---|---|
| 조사 대상 기간 | 2026-2031년 |
| 기준 연도 | 2025년 |
| 예측 기간 | 2026-2031년 |
| 산정 단위 | 금액(10억 달러) |
| 부문 | 제품별, 기술별, 유형별, 체액 유형별, 용도별, 최종사용자별, 지역별 |
| 대상 지역 | 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
또한, 자동 분석기, 유세포 분석법, 면역 측정법 및 분자진단 기술의 발전으로 인해 특수 체액 검사의 정확성, 효율성 및 표준화가 향상되고 있습니다. 이러한 혁신 덕분에 의료 종사자들은 보다 정확한 진단 및 치료 결정을 내릴 수 있게 되었으며, 이는 결과적으로 시장의 성장을 뒷받침하고 있습니다.
"예측 기간 동안 용도별로는 임상 진단 부문이 체액 분석 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다."
용도에 따라 체액 분석 시장은 임상 진단, 법의학 및 조사 용도로 분류됩니다. 신경 질환, 감염증, 암, 염증성 질환, 생식기 질환의 진단 및 모니터링에 체액 분석이 점점 더 많이 활용됨에 따라, 임상 진단 부문이 가장 큰 시장 점유율을 차지하고 있습니다. 임상 검사실이나 병원에서는 뇌척수액(CSF), 흉수, 복수, 활액 및 기타 특수한 체액을 분석하기 위해 유세포 분석법, 면역측정법, 임상화학, 분자진단 등의 기술이 널리 활용되고 있습니다. 또한, 질환의 조기 발견, 정밀 진단, 근거에 기반한 임상적 의사결정에 대한 관심이 높아짐에 따라 일상적인 의료 현장에서 체액 분석에 대한 수요가 지속적으로 확대되고 있으며, 임상 진단은 시장에서 가장 규모가 크고 가장 빠르게 성장하고 있는 응용 분야가 되고 있습니다.
"예측 기간 동안 임상화학이 체액 분석 시장에서 가장 큰 점유율을 차지할 것으로 전망됩니다."
세계 체액 분석 시장은 기술별로 현미경 검사, 임상화학, 유세포 분석법, 면역측정법, 중합효소 연쇄 반응(PCR), 기타 기술로 분류할 수 있습니다. 이 중 임상화학 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 전망됩니다. 임상화학 검사는 그 확립된 임상적 유용성, 의료 시설 전반에 걸친 광범위한 활용 가능성, 그리고 신속한 진단 판단을 지원하는 능력 덕분에 일상적인 체액 평가의 기초적인 요소로 자리 잡고 있습니다. 또한, 자동 화학 분석 장치의 지속적인 발전, 검사 건수의 증가, 그리고 표준화된 진단 워크플로우에 대한 수요 증가가 전 세계적으로 임상 화학을 기반으로 한 체액 분석의 지속적인 도입을 촉진할 것으로 예상됩니다.
"아시아태평양 : 2026년부터 2031년까지 체액 분석 검사 시장에서 가장 빠르게 성장할 지역"
세계 체액 분석 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 구분됩니다. 아시아태평양은 2026년부터 2031년까지 지역별 가장 높은 연평균 성장률(CAGR)을 기록하며 성장할 것으로 전망됩니다. 일본에서는 고령화가 진행되고 있으며, 이로 인해 뇌척수액(CSF)을 이용한 신경퇴행성 질환 진단에 대한 수요가 증가하고 있습니다. 중국에서는 국가 차원의 의료 현대화 프로그램을 통해 병원 검사실의 처리 능력이 확대되고 있습니다. 인도에서는 3차 의료 병원 및 민간 진단 센터 네트워크를 통해 자동화된 체액 분석 시스템의 도입이 진행되고 있습니다.
Sysmex Corporation(일본), F. Hoffmann-La Roche Ltd.(스위스), Danaher Corporation(미국), bioMerieux SA(프랑스), Abbott Laboratories(미국), Thermo Fisher Scientific Inc.(미국), QIAGEN N.V.(네덜란드), Revvity, Inc.(미국), Siemens Healthineers AG(독일), Becton, Dickinson and Company(미국), HORIBA, Ltd.(일본), Bio-Rad Laboratories, Inc.(미국), 및 DiaSorin S.p.A.(이탈리아) 등이 체액 분석 시장의 주요 기업 중 일부입니다.
조사 범위:
본 조사 보고서에서는 체액 분석 시장을 제품별(소모품 및 기기), 기술별(현미경 검사, 임상화학, 유세포 분석, 면역측정법, 중합효소 연쇄 반응(PCR), 기타 기술), 종류별(채취 기구 및 진단 제품), 체액 종류별(뇌척수액, 흉수, 복수, 활액, 정액, 심막액), 용도(임상 진단, 법의학, 조사), 최종사용자(병원 검사실, 진단 검사실, 법의학 검사실, 학술·연구 기관, 제약·생명공학 기업), 및 지역(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카)별로 분류하고 있습니다. 본 보고서의 조사 범위에는 체액 분석 시장의 성장에 영향을 미치는 주요 요인(촉진요인, 제약요인, 기회, 과제 등)에 관한 상세한 정보가 포함되어 있습니다. 주요 업계 기업들에 대한 상세한 분석을 통해 각 기업의 사업 개요, 솔루션, 인수, 계약, 제품 및 서비스 출시와 같은 주요 전략은 물론, 체액 분석 시장과 관련된 최근 동향에 대한 인사이트를 제공합니다. 또한, 체액 분석 시장의 생태계에서 두각을 나타내고 있는 스타트업 기업에 대한 경쟁 분석도 본 보고서에서 다루고 있습니다.
이 보고서를 구매해야 하는 이유:
본 보고서는 체액 분석 시장 전체 및 각 하위 부문의 매출에 관한 가장 정확한 추정치를 제공함으로써, 이 시장의 선도 기업과 신규 진입 기업을 지원합니다. 본 보고서는 이해관계자들이 시장 상황을 이해하고, 자사의 비즈니스를 더 유리한 위치에 놓으며, 적절한 시장 진입 전략을 수립하는 데 필요한 추가적인 인사이트를 얻는 데 도움이 됩니다. 또한, 본 보고서는 이해관계자들이 시장 동향을 파악할 수 있도록 지원하며, 주요 시장 촉진요인 및 과제에 관한 정보를 제공합니다.
본 보고서에서는 다음 사항에 대한 인사이트를 제공합니다:
- 체액 분석 시장의 성장에 영향을 미치는 주요 촉진요인(전 세계 질병 부담 증가, 생식 건강 관련 질환 및 불임 유병률 상승, 질병 조기 발견에 대한 인식 제고), 제약요인(표준화된 보험 급여 제도의 부재, 장비 및 소모품의 높은 비용, 숙련된 검사 기술자 부족), 기회(신흥 경제권에서의 확장 가능성, 진단 기술의 발전), 그리고 과제(엄격하고 다양한 규제 요건, 시약 및 키트 공급망의 혼란)에 대해 분석하고 있습니다. 이것들은 체액 분석 시장의 성장에 영향을 미치는 요인들입니다.
- 제품 개발/혁신 : 체액 분석 시장의 향후 기술 동향, 연구개발 활동 및 신제품 출시에 관한 상세한 분석.
- 시장 개발 : 수익성이 높은 시장에 대한 종합적인 정보 -- 본 보고서에서는 다양한 지역의 체액 분석 시장을 분석하고 있습니다.
- 시장의 다양화 : 체액 분석 시장의 신제품, 미개척 지역, 최근 동향 및 투자에 관한 종합적인 정보
- 경쟁사 분석 : Danaher(미국), F. Hoffmann-La Roche Ltd.(스위스), Thermo Fisher Scientific Inc.(미국), Becton, Dickinson and Company(미국), Abbott(미국) 등 주요 기업의 시장 점유율, 성장 전략, 제품 라인업에 대한 상세한 평가.
자주 묻는 질문
목차
제1장 소개
제2장 주요 요약
제3장 주요 인사이트
제4장 시장 개요
제5장 업계 동향
제6장 기술 진보, AI에 의한 영향, 특허, 혁신, 그리고 향후 응용
제7장 규제 상황과 지속가능성에 대한 대처
제8장 고객 상황과 구매 행동
제9장 체액 분석 시장(제품별)
제10장 체액 분석 시장(기술별)
제11장 체액 분석 시장(유형별)
제12장 체액 분석 시장(체액 유형별)
제13장 체액 분석 시장 수량 분석(체액 유형별, 검사 건수)
제14장 체액 분석 시장(용도별)
제15장 체액 분석 시장(최종사용자별)
제16장 체액 분석 시장(지역별)
제17장 경쟁 구도
제18장 기업 개요
제19장 조사 방법
제20장 부록
KSM 26.07.20The body fluid analysis market is projected to grow from USD 2.62 billion in 2026 to USD 3.65 billion by 2031, growing at a CAGR of 6.9%. The increasing prevalence of neurological disorders such as Alzheimer's disease and Parkinson's disease is driving demand for cerebrospinal fluid (CSF) biomarker testing, while the growing incidence of musculoskeletal disorders and periprosthetic joint infections is expanding the use of synovial fluid analysis.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | By Product, Technology, Type, Fluid Type, Application, End User |
| Regions covered | North America, Europe, APAC, LATAM, MEA |
Furthermore, advancements in automated analyzers, flow cytometry, immunoassays, and molecular diagnostic technologies are improving the accuracy, efficiency, and standardization of specialty body fluid testing. These innovations are enabling healthcare providers to make more informed diagnostic and treatment decisions, thereby supporting market growth.
"The clinical diagnostics segment is expected to account for the largest share of the body fluid analysis market, by application, during the forecast period."
Depending on the application, the body fluid analysis market is classified into clinical diagnostics, forensics, and research applications. The clinical diagnostics segment accounts for the largest market share due to the increasing use of body fluid analysis for the diagnosis and monitoring of neurological disorders, infections, cancers, inflammatory conditions, and reproductive health disorders. Clinical laboratories and hospitals extensively utilize technologies such as flow cytometry, immunoassays, clinical chemistry, and molecular diagnostics to analyze cerebrospinal fluid (CSF), pleural fluid, peritoneal fluid, synovial fluid, and other specialty body fluids. Additionally, the growing emphasis on early disease detection, precision diagnostics, and evidence-based clinical decision-making continues to drive demand for body fluid analysis in routine healthcare settings, making clinical diagnostics the largest and fastest-growing application segment of the market.
"The clinical chemistry is likely to capture the largest share of the body fluid analysis market throughout the forecast period."
The global body fluid analysis market can be segmented by technology into microscopic examination, clinical chemistry, flow cytometry, immunoassay, polymerase chain reaction (PCR), and other technologies. Among these, the clinical chemistry segment is likely to account for the largest market share throughout the forecast period. Clinical chemistry testing remains a fundamental component of routine body fluid evaluation due to its established clinical utility, broad availability across healthcare facilities, and ability to support rapid diagnostic decision-making. Furthermore, continuous advancements in automated chemistry analyzers, increasing laboratory testing volumes, and growing demand for standardized diagnostic workflows are expected to support the continued adoption of clinical chemistry-based body fluid analysis worldwide.
"Asia Pacific: The fastest-growing market for body fluid analysis testing from 2026 to 2031"
The global body fluid analysis market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa. Asia Pacific is projected to grow at the highest regional CAGR from 2026 to 2031. Japan has a large aging population driving demand for CSF-based neurodegenerative diagnostics. China is expanding hospital laboratory capacity through national health modernization programs. India's network of tertiary-care hospitals and private diagnostic centers is adopting automated body fluid analysis systems.
The break-up of the profile of primary participants in the body fluid analysis market:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier - 30%
- By Designation: C-level Executives - 27%, Directors - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa - 4%
Sysmex Corporation (Japan); F. Hoffmann-La Roche Ltd. (Switzerland); Danaher Corporation (US); bioMerieux SA (France); Abbott Laboratories (US); Thermo Fisher Scientific Inc. (US); QIAGEN N.V. (Netherlands); Revvity, Inc. (US); Siemens Healthineers AG (Germany); Becton, Dickinson and Company (US); HORIBA, Ltd. (Japan); Bio-Rad Laboratories, Inc. (US); and DiaSorin S.p.A. (Italy) are some of the key players in the body fluid analysis market.
Research Coverage:
This research report categorizes the body fluid analysis market by product (consumables and instruments), by technology (microscopic examination, clinical chemistry, flow cytometry, immunoassay, polymerase chain reaction, and other technologies), by type (collection devices and diagnostic products), by fluid type (cerebrospinal fluid, pleural fluid, peritoneal fluid, synovial fluid, semen, and pericardial fluid), by application (clinical diagnostics, forensic, and research), by end user (hospital laboratories, diagnostic laboratories, forensic laboratories, academic and research institutes, and pharmaceutical and biotechnology companies), and by region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the body fluid analysis market. A detailed analysis of the key industry players has been done to provide insights into their business overview; solutions; key strategies such as acquisitions, agreements, and product & service launches; and recent developments associated with the body fluid analysis market. Competitive analysis of upcoming startups in the body fluid analysis market ecosystem is covered in this report.
Reasons to Buy This Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall body fluid analysis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (growing global disease burden, increasing prevalence of reproductive health conditions and infertility, growing awareness of early disease detection), restraints (lack of standardized reimbursement structures, high cost of instruments and consumables, shortage of skilled laboratory personnel), opportunities (expansion potential across emerging economies, advancements in diagnostic technologies), and challenges (stringent and varying regulatory requirements, supply chain disruptions for reagents and kits) influencing the growth of the body fluid analysis market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the body fluid analysis market.
- Market Development: Comprehensive information about lucrative markets-the report analyzes the body fluid analysis market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the body fluid analysis market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Danaher (US); F. Hoffmann-La Roche Ltd. (Switzerland); Thermo Fisher Scientific Inc. (US); Becton, Dickinson and Company (US); and Abbott (US).
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
- 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
- 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
- 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 BODY FLUID ANALYSIS MARKET OVERVIEW
- 3.2 BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2026 VS. 2031
- 3.3 BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2026 VS. 2031
- 3.4 BODY FLUID ANALYSIS MARKET, BY TYPE, 2026 VS. 2031
- 3.5 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2026 VS. 2031
- 3.6 BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2026 VS. 2031
- 3.7 BODY FLUID ANALYSIS MARKET, BY END USER, 2026 VS. 2031
- 3.8 BODY FLUID ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Growing global infectious disease, inflammatory disease, and cancer burden necessitating body fluid analysis
- 4.2.1.2 Increasing prevalence of reproductive health conditions and infertility
- 4.2.1.3 Growing awareness of early disease detection
- 4.2.2 RESTRAINTS
- 4.2.2.1 Limited and inconsistent reimbursement for advanced body fluid testing
- 4.2.2.2 High cost of instruments and consumables
- 4.2.2.3 Shortage of skilled laboratory personnel
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Expansion potential across emerging economies
- 4.2.3.2 Advancements in diagnostic technologies
- 4.2.4 CHALLENGES
- 4.2.4.1 Stringent and varying regulatory requirements
- 4.2.4.2 Supply chain disruptions for reagents and kits
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS AND WHITE SPACES
- 4.3.1 UNMET NEEDS IN BODY FLUID ANALYSIS MARKET
- 4.3.2 WHITE SPACE OPPORTUNITIES
- 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
- 4.4.1 INTERCONNECTED MARKETS
- 4.4.2 CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
- 4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 BARGAINING POWER OF SUPPLIERS
- 5.1.2 BARGAINING POWER OF BUYERS
- 5.1.3 THREAT OF NEW ENTRANTS
- 5.1.4 THREAT OF SUBSTITUTES
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMIC OUTLOOK
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS AND FORECAST
- 5.3 SUPPLY CHAIN ANALYSIS
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
- 5.5.1 BODY FLUID ANALYSIS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
- 5.6 PRICING ANALYSIS
- 5.6.1 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY KEY PLAYER, 2024-2026
- 5.6.2 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY REGION, 2024-2026
- 5.7 TRADE ANALYSIS
- 5.7.1 IMPORT SCENARIO (HS CODE 3822)
- 5.7.2 EXPORT SCENARIO (HS CODE 3822)
- 5.8 KEY CONFERENCES & EVENTS, 2026-2027
- 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.10 INVESTMENT & FUNDING SCENARIO
- 5.11 CASE STUDY ANALYSIS
- 5.11.1 CASE STUDY 1: IMPLEMENTATION OF AUTOMATED CSF ALZHEIMER'S BIOMARKER TESTING USING ROCHE ELECSYS ASSAYS
- 5.11.2 CASE STUDY 2: IMPLEMENTATION OF AUTOMATED BODY FLUID CELL COUNTING USING BECKMAN COLTER UNICEL DXH SERIES
- 5.11.3 CASE STUDY 3: POINT-OF-CARE TESTING FOR PLEURAL, PERITONEAL, AND CSF ANALYSIS
- 5.12 IMPACT OF US TARIFFS-BODY FLUID ANALYSIS MARKET
- 5.12.1 INTRODUCTION
- 5.12.2 KEY TARIFF RATES
- 5.12.3 PRICE IMPACT ANALYSIS
- 5.12.4 IMPACT ON COUNTRIES/REGIONS
- 5.12.4.1 North America
- 5.12.4.2 Europe
- 5.12.4.3 Asia Pacific
- 5.12.5 IMPACT ON END-USE INDUSTRIES
- 5.12.5.1 Diagnostic laboratories
- 5.12.5.2 Hospital laboratories
- 5.12.5.3 Forensic laboratories
- 5.12.5.4 Academic & research institutes
- 5.12.5.5 Pharmaceutical & biotechnology companies
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
- 6.1 KEY EMERGING TECHNOLOGIES
- 6.1.1 FLOW CYTOMETRY
- 6.1.2 PCR
- 6.2 COMPLEMENTARY TECHNOLOGIES
- 6.2.1 BIOINFORMATICS & DATA ANALYTICS PLATFORMS
- 6.3 ADJACENT TECHNOLOGIES
- 6.3.1 DIGITAL PCR (DPCR)
- 6.4 TECHNOLOGY/PRODUCT ROADMAP
- 6.5 PATENT ANALYSIS
- 6.5.1 LIST OF MAJOR PATENTS
- 6.6 FUTURE APPLICATIONS
- 6.7 IMPACT OF AI/GENERATIVE AI ON BODY FLUID ANALYSIS MARKET
- 6.7.1 INTRODUCTION
- 6.7.2 TOP USE CASES AND MARKET POTENTIAL
- 6.7.3 KEY COMPANIES IMPLEMENTING AI
- 6.7.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
- 7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY ANALYSIS
- 7.1.1.1 North America
- 7.1.1.1.1 US
- 7.1.1.1.2 Canada
- 7.1.1.2 Europe
- 7.1.1.2.1 Germany
- 7.1.1.2.2 UK
- 7.1.1.2.3 France
- 7.1.1.2.4 Italy
- 7.1.1.3 Asia Pacific
- 7.1.1.3.1 China
- 7.1.1.3.2 Japan
- 7.1.1.3.3 India
- 7.1.1.4 Latin America
- 7.1.1.4.1 Brazil
- 7.1.1.4.2 Mexico
- 7.1.1.5 Middle East
- 7.1.1.5.1 Africa
- 7.1.1.1 North America
- 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.1 REGULATORY ANALYSIS
- 7.2 SUSTAINABILITY INITIATIVES
- 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN BODY FLUID ANALYSIS MARKET
- 7.2.1.1 Eco-friendly Initiatives
- 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN BODY FLUID ANALYSIS MARKET
- 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 DECISION-MAKING PROCESS
- 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 BUYING CRITERIA
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
- 8.5 MARKET PROFITABILITY
- 8.5.1 REVENUE POTENTIAL
- 8.5.2 COST DYNAMICS
- 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 BODY FLUID ANALYSIS MARKET, BY PRODUCT
- 9.1 INTRODUCTION
- 9.2 CONSUMABLES
- 9.2.1 ONGOING INNOVATIONS IN BODY FLUID ANALYSIS TO SPUR GROWTH
- 9.3 INSTRUMENTS
- 9.3.1 TECHNOLOGICAL ADVANCEMENTS TO FOSTER MARKET GROWTH
10 BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY
- 10.1 INTRODUCTION
- 10.2 MICROSCOPIC EXAMINATION
- 10.2.1 GROWING ADOPTION OF AUTOMATED AND DIGITAL MICROSCOPY TO DRIVE MARKET
- 10.3 CLINICAL CHEMISTRY
- 10.3.1 RISING DEMAND FOR RAPID AND ACCURATE BIOCHEMICAL ASSESSMENT FUELS ADOPTION OF CLINICAL CHEMISTRY TECHNOLOGY
- 10.4 FLOW CYTOMETRY
- 10.4.1 ADVANCEMENTS IN MULTIPARAMETRIC ANALYSIS AND AUTOMATION DRIVE THE MARKET GROWTH
- 10.5 IMMUNOASSAY
- 10.5.1 INCREASING USE OF IMMUNOASSAYS IN CANCER AND INFECTIOUS DISEASE TESTING TO AID GROWTH
- 10.6 POLYMERASE CHAIN REACTION
- 10.6.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH
- 10.7 OTHER TECHNOLOGIES
11 BODY FLUID ANALYSIS MARKET, BY TYPE
- 11.1 INTRODUCTION
- 11.2 COLLECTION DEVICES
- 11.2.1 RISING DEMAND FOR ACCURATE SPECIMEN COLLECTION AND HANDLING TO PROMOTE GROWTH
- 11.3 DIAGNOSTIC PRODUCTS
- 11.3.1 TECHNOLOGICAL ADVANCEMENTS TO AUGMENT GROWTH
12 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE
- 12.1 INTRODUCTION
- 12.2 CEREBROSPINAL FLUID
- 12.2.1 INCREASING BURDEN OF NEUROLOGICAL DISORDERS SUPPORTS MARKET GROWTH
- 12.3 PLEURAL FLUID
- 12.3.1 TECHNOLOGICAL ADVANCEMENTS IMPROVING DIAGNOSTIC ACCURACY OF PLEURAL FLUID TESTING TO DRIVE MARKET
- 12.4 PERITONEAL FLUID
- 12.4.1 RISING PREVALENCE OF LIVER DISORDERS AND MALIGNANT ASCITES DRIVES MARKET
- 12.5 SYNOVIAL FLUID
- 12.5.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET
- 12.6 SEMEN
- 12.6.1 DECLINING MALE REPRODUCTIVE HEALTH DRIVING DEMAND FOR SEMEN ANALYSIS
- 12.7 PERICARDIAL FLUID
- 12.7.1 GROWING UTILIZATION OF PERICARDIAL FLUID TESTING IN CLINICAL PRACTICES TO DRIVE MARKET
13 BODY FLUID ANALYSIS MARKET VOLUME ANALYSIS, BY FLUID TYPE (NUMBER OF TESTS)
14 BODY FLUID ANALYSIS MARKET, BY APPLICATION
- 14.1 INTRODUCTION
- 14.2 CLINICAL DIAGNOSTICS
- 14.2.1 INFECTIOUS DISEASES
- 14.2.1.1 Rising burden of infectious diseases drives adoption of body fluid analysis
- 14.2.2 INFLAMMATORY DISEASES
- 14.2.2.1 Growing burden of autoimmune and inflammatory diseases supports market growth
- 14.2.3 CANCER
- 14.2.3.1 Rising burden of cancer to fuel growth
- 14.2.4 OTHER DISEASES
- 14.2.1 INFECTIOUS DISEASES
- 14.3 FORENSICS
- 14.3.1 GROWING UTILIZATION OF BODY FLUID ANALYSIS IN FORENSIC AND MEDICO-LEGAL INVESTIGATIONS TO SUPPORT MARKET
- 14.4 RESEARCH
- 14.4.1 INCREASING USE OF BODY FLUID ANALYSIS IN BIOMEDICAL RESEARCH AND BIOMARKER DISCOVERY TO BOOST MARKET
15 BODY FLUID ANALYSIS MARKET, BY END USER
- 15.1 INTRODUCTION
- 15.2 HOSPITAL LABORATORIES
- 15.2.1 RISING HEALTHCARE INVESTMENT TO CONTRIBUTE TO GROWTH
- 15.3 DIAGNOSTIC LABORATORIES
- 15.3.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET
- 15.4 FORENSIC LABORATORIES
- 15.4.1 ADVANCEMENTS IN FORENSIC TESTING AND LABORATORY INFORMATICS SUPPORT MARKET GROWTH
- 15.5 ACADEMIC & RESEARCH INSTITUTES
- 15.5.1 ADVANCEMENTS IN RESEARCH TO BOOST MARKET
- 15.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 15.6.1 INCREASING ADOPTION OF BIOMARKER-DRIVEN DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH
16 BODY FLUID ANALYSIS MARKET, BY REGION
- 16.1 INTRODUCTION
- 16.2 NORTH AMERICA
- 16.2.1 US
- 16.2.1.1 Presence of advanced healthcare infrastructure to augment growth
- 16.2.2 CANADA
- 16.2.2.1 Favorable government initiatives to fuel market
- 16.2.1 US
- 16.3 EUROPE
- 16.3.1 GERMANY
- 16.3.1.1 Increasing healthcare expenditure to advance growth
- 16.3.2 UK
- 16.3.2.1 Growing number of diagnostic centers to fuel market
- 16.3.3 FRANCE
- 16.3.3.1 Increasing demand for early disease diagnosis to augment growth
- 16.3.4 ITALY
- 16.3.4.1 Growing adoption of advanced diagnostic technologies to fuel market
- 16.3.5 SPAIN
- 16.3.5.1 Increased government initiatives to boost market
- 16.3.6 REST OF EUROPE
- 16.3.1 GERMANY
- 16.4 ASIA PACIFIC
- 16.4.1 CHINA
- 16.4.1.1 Rising public access to modern healthcare to spur growth
- 16.4.2 JAPAN
- 16.4.2.1 Universal healthcare reimbursement policy to foster growth
- 16.4.3 INDIA
- 16.4.3.1 Increased government investments for healthcare sector to bolster growth
- 16.4.4 REST OF ASIA PACIFIC
- 16.4.1 CHINA
- 16.5 LATIN AMERICA
- 16.5.1 RISING DISEASE INCIDENCE AND HEALTHCARE INFRASTRUCTURAL IMPROVEMENTS TO DRIVE MARKET
- 16.6 MIDDLE EAST & AFRICA
- 16.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH
17 COMPETITIVE LANDSCAPE
- 17.1 INTRODUCTION
- 17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 17.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BODY FLUID ANALYSIS MARKET
- 17.3 REVENUE ANALYSIS, 2023-2025
- 17.4 MARKET SHARE ANALYSIS, 2025
- 17.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
- 17.4.2 US MARKET SHARE ANALYSIS, 2025
- 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 17.5.1 STARS
- 17.5.2 EMERGING LEADERS
- 17.5.3 PERVASIVE PLAYERS
- 17.5.4 PARTICIPANTS
- 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 17.5.5.1 Company footprint
- 17.5.5.2 Region footprint
- 17.5.5.3 Product footprint
- 17.5.5.4 Type footprint
- 17.5.5.5 Application footprint
- 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 17.6.1 PROGRESSIVE COMPANIES
- 17.6.2 RESPONSIVE COMPANIES
- 17.6.3 DYNAMIC COMPANIES
- 17.6.4 STARTING BLOCKS
- 17.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 17.6.5.1 Detailed list of key startups/SMEs
- 17.6.5.2 Competitive benchmarking of startups/SMEs
- 17.7 COMPANY VALUATION & FINANCIAL METRICS
- 17.7.1 FINANCIAL METRICS
- 17.7.2 COMPANY VALUATION
- 17.8 PRODUCT COMPARISON
- 17.9 COMPETITIVE SCENARIO
- 17.9.1 PRODUCT LAUNCHES & APPROVALS
- 17.9.2 DEALS
- 17.9.3 EXPANSIONS
18 COMPANY PROFILES
- 18.1 KEY PLAYERS
- 18.1.1 DANAHER
- 18.1.1.1 Business overview
- 18.1.1.2 Products offered
- 18.1.1.3 Recent developments
- 18.1.1.3.1 Deals
- 18.1.1.4 MnM view
- 18.1.1.4.1 Key strengths
- 18.1.1.4.2 Strategic choices
- 18.1.1.4.3 Weaknesses and competitive threats
- 18.1.2 F. HOFFMANN-LA ROCHE LTD
- 18.1.2.1 Business overview
- 18.1.2.2 Products offered
- 18.1.2.3 Recent developments
- 18.1.2.3.1 Product launches & approvals
- 18.1.2.4 MnM view
- 18.1.2.4.1 Key strengths
- 18.1.2.4.2 Strategic choices
- 18.1.2.4.3 Weaknesses and competitive threats
- 18.1.3 BECTON, DICKINSON AND COMPANY (BD)
- 18.1.3.1 Business overview
- 18.1.3.2 Products offered
- 18.1.3.3 MnM view
- 18.1.3.3.1 Key strengths
- 18.1.3.3.2 Strategic choices
- 18.1.3.3.3 Weaknesses and competitive threats
- 18.1.4 ABBOTT
- 18.1.4.1 Business overview
- 18.1.4.2 Products offered
- 18.1.4.3 MnM view
- 18.1.4.3.1 Key strengths
- 18.1.4.3.2 Strategic choices
- 18.1.4.3.3 Weaknesses & competitive threats
- 18.1.5 THERMO FISHER SCIENTIFIC INC.
- 18.1.5.1 Business overview
- 18.1.5.2 Products offered
- 18.1.5.3 Recent developments
- 18.1.5.3.1 Expansions
- 18.1.5.4 MnM view
- 18.1.5.4.1 Key strengths
- 18.1.5.4.2 Strategic choices
- 18.1.5.4.3 Weaknesses and competitive threats
- 18.1.6 SIEMENS HEALTHINEERS AG
- 18.1.6.1 Business overview
- 18.1.6.2 Products offered
- 18.1.6.3 Recent developments
- 18.1.6.3.1 Deals
- 18.1.6.3.2 Expansions
- 18.1.7 BIOMERIEUX
- 18.1.7.1 Business overview
- 18.1.7.2 Products offered
- 18.1.8 SYSMEX CORPORATION
- 18.1.8.1 Business overview
- 18.1.8.2 Products offered
- 18.1.8.3 Recent developments
- 18.1.8.3.1 Deals
- 18.1.9 BIO-RAD LABORATORIES
- 18.1.9.1 Business overview
- 18.1.9.2 Products offered
- 18.1.10 QIAGEN
- 18.1.10.1 Business overview
- 18.1.10.2 Products offered
- 18.1.10.3 Recent developments
- 18.1.10.3.1 Product launches and approvals
- 18.1.11 REVVITY
- 18.1.11.1 Business overview
- 18.1.11.2 Products offered
- 18.1.12 DIASORIN S.P.A.
- 18.1.12.1 Business overview
- 18.1.12.2 Products offered
- 18.1.13 HORIBA, LTD.
- 18.1.13.1 Business overview
- 18.1.13.2 Products offered
- 18.1.1 DANAHER
- 18.2 OTHER PLAYERS
- 18.2.1 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
- 18.2.2 VIRCELL S.L.
- 18.2.3 FUJIREBIO
- 18.2.4 ERBA GROUP
- 18.2.5 GUANGZHOU WONDFO BIOTECH CO., LTD.
- 18.2.6 MESO SCALE DIAGNOSTICS, LLC
- 18.2.7 RANDOX LABORATORIES LTD.
- 18.2.8 AMPRION DIAGNOSTICS
- 18.2.9 ATILA BIOSYSTEMS
- 18.2.10 QUANTERIX
- 18.2.11 ALAMAR BIOSCIENCES
- 18.2.12 GENEPROOF
19 RESEARCH METHODOLOGY
- 19.1 RESEARCH DATA
- 19.1.1 SECONDARY DATA
- 19.1.1.1 List of secondary sources
- 19.1.1.2 Key data from secondary sources
- 19.1.2 PRIMARY DATA
- 19.1.2.1 List of primary sources
- 19.1.2.2 Key data from primary sources
- 19.1.2.3 Key industry insights
- 19.1.2.4 Breakdown of primary interviews
- 19.1.1 SECONDARY DATA
- 19.2 MARKET SIZE ESTIMATION
- 19.2.1 TOTAL MARKET SIZE: BODY FLUID ANALYSIS MARKET
- 19.2.2 BOTTOM-UP APPROACH
- 19.2.2.1 Approach 1: Revenue estimation of key players
- 19.2.2.2 Approach 2: Study of annual reports and investor presentations
- 19.2.2.3 Approach 3: Primary interviews
- 19.2.2.4 Growth forecast
- 19.2.2.5 CAGR projections
- 19.2.3 TOP-DOWN APPROACH
- 19.3 DATA TRIANGULATION
- 19.4 RESEARCH ASSUMPTIONS
- 19.4.1 STUDY-RELATED ASSUMPTIONS
- 19.5 STUDY ASSUMPTIONS
- 19.5.1 PARAMETRIC ASSUMPTIONS
- 19.5.2 GROWTH RATE ASSUMPTIONS
- 19.6 RESEARCH LIMITATIONS
- 19.7 RISK ASSESSMENT
20 APPENDIX
- 20.1 DISCUSSION GUIDE
- 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 20.3 CUSTOMIZATION OPTIONS
- 20.4 RELATED REPORTS
- 20.5 AUTHOR DETAILS
